Boston Scientific
Q1 2022 Earnings Call
Apr 27, 2022, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning, and welcome to the Boston Scientific first quarter 2022 earnings call. [Operator instructions] I would now like to turn the conference over to Lauren Tengler, vice president, investor relations. Please go ahead.
Lauren Tengler -- Vice President, Investor Relations
Thank you, Andrew. Welcome, everyone, and thanks for joining us today. With me on today's call are Mike Mahoney, chairman and chief executive officer; and Dan Brennan, executive vice president and chief financial officer. We issued a press release earlier this morning announcing our Q1 2022 results, which included reconciliations of the non-GAAP measure used in the release.
We have posted a copy of that release, as well as reconciliations of the non-GAAP measures used in today's call to the investor relations section of our website under the heading, financials and filings. The duration of this morning's call will be approximately one hour. Michael focused his comments on Q1 performance, as well as future catalysts and the outlook for our business, including Q2 2022 and full year '22 guidance. Dan will review the financials for the quarter, provide more details regarding our Q2 and full year 2022 guidance.
And then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our chief medical officers, Dr. Ian Meredith and Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on the call, operational revenue growth excludes the impact of foreign currency fluctuations, and organic revenue growth further excludes acquisitions and divestitures for which there is less than a full period of comparable net sales. Relevant acquisitions excluded for organic growth are Preventice, Farapulse, and Lumenis surgical, which closed in March, August, and September of 2021, respectively, as well as Baylis Medical, which closed on February 14, 2022. Divestitures include the BTG Spec Pharma business, which closed on March 1, 2021. For more information, please refer to our financial and operating highlights deck, which may be found on our investor relations website.
On this call, all references to sales and revenue, unless otherwise specified, are organic. This call contains forward-looking statements within the meaning of federal securities laws, which might be identified by words like anticipate, expect, may, believe, estimate, and other similar words. They include, among other things, the impact of COVID-19 pandemic upon the company's operations and financial results; statements about our growth and market share; new product approvals and launches; acquisitions; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, and earnings; as well as our tax rates, R&D spend, and other expenses. Factors that may cause such differences include those described in the risk factors section of our most recent 10-K and subsequent 10-Q filed with the SEC.